Recent Transactions

02-Mar-98
$400 million
Italy flag
Target: 

Olsy SpA (Olivetti SpA)

United States flag
Acquiror: 
Wang Laboratories Inc.

Advised Wang on its acquisition of Olsy, the systems and solutions division of Olivetti, for a combination of cash and securities.

30-Jul-01
$117 million
United Kingdom flag
Target: 

Kymata Ltd.

France flag
Acquiror: 
Alcatel Optronics

Advised Kymata Ltd, the Scottish manufacturer of optical components, on its sale to Alcatel Optronics of France.

24-Mar-06
$21.2 billion
Germany flag
Target: 

Schering AG

Germany flag
Acquiror: 
Bayer AG

Advised Bayer on its public offer for Schering, an international pharmaceuticals group based in Berlin, Germany

19-Dec-06
$270 million
United States flag
Target: 

Brion Technologies, Inc.

Netherlands flag
Acquiror: 
ASML Holding N.V.

Advised ASML Holding N.V., a leading provider of lithography systems for the semiconductor industry, on its acquisition of Brion Technologies, Inc.

22-Jan-08
$3.4 billion
United States flag
Target: 

Ventana Medical Systems, Inc.

Switzerland flag
Acquiror: 
Roche Holding Ltd.

Advised Roche Holding Ltd., a world-leading provider of healthcare pharmaceuticals and diagnostics, on its acquisition of Ventana Medical Systems, Inc., a US based provider of histopathology diagnostic equipment

05-Aug-08
$NA
Germany flag
Target: 

BARTEC Group

Switzerland flag
Acquiror: 
Capvis

Advised Capvis, a leading Swiss private equity firm, on its acquisition of the BARTEC Group, a leading European provider of industrial safety technology, from Allianz Capital Partners, the captive private equity arm of Allianz AG, and the Barlian family (founding family)

15-Sep-08
$189 million
Belgium flag
Target: 

Fermat International

United States flag
Acquiror: 
Moody’s Corporation

Advised Moody’s Corporation on its acquisition of Fermat International, a leading provider of risk and performance management software to the global banking sector

01-Oct-08
$53 million
Sweden flag
Target: 

Biotage (Biosystems division)

Netherlands flag
Acquiror: 
Qiagen NV

Advised Biotage AB (OMX: BIOT), a global biotechnology company, on its strategic review resulting in the disposal of its Biosystems division which offers systems for genetic analysis mainly for use in clinical research

12-Mar-09
$46.9 billion
United States flag
Target: 

Genentech, Inc.

Switzerland flag
Acquiror: 
Roche Holding Ltd.

Advised Roche Holding Ltd., a world-leading provider of healthcare pharmaceuticals and diagnostics, on its acquisition of the outstanding publicly held interest in Genentech, Inc., a leading biotechnology company

09-Nov-09
$327 million
United States flag
Target: 

Enzon Pharmaceuticals, Inc.

Italy flag
Acquiror: 
Sigma-Tau Pharmaceuticals

Advised Enzon Pharmaceuticals, Inc., a biopharmaceutical company on the sale of its specialty pharmaceutical business to Sigma-Tau, an Italian pharmaceutical company

04-Dec-09
$NA
Germany flag
Target: 

Verivox Holding Limited

United Kingdom flag
Acquiror: 
Oakley Capital Private Equity LP

Advised the shareholders of Verivox Holdings Limited, comprising Independent News & Media plc and the founders and joint CEOs of Verivox, on the sale of 51% in Verivox, Germany’s leading price comparison website for energy and telecommunications services, to Oakley Capital Private Equity

23-Sep-10
$394 million
Australia flag
Target: 

Aevum Ltd.

Australia flag
Acquiror: 
Stockland Corp. Ltd

Advised Aevum Limited, an ASX listed owner, operator and developer of retirement villages and aged care facilities on its response to a hostile takeover offer from Stockland Ltd, a global property development and investment management group

26-Nov-10
$118 million
Australia flag
Target: 

Healthcare Australia

United Kingdom flag
Acquiror: 
Healthcare Locums

Advised CHAMP Private Equity on the sale of Healthcare Australia, a leading provider of nursing agency staff to public and private health institutions in Australia, to Healthcare Locums, a healthcare recruitment agency based in the UK

15-Dec-10
$12.9 billion
U.S.A., Swiss flags
Target: 

Alcon, Inc.

Switzerland flag
Acquiror: 
Novartis AG

Advised the Independent Director Committee of Alcon, Inc., an ophthalmic pharmaceutical company, on the sale of Alcon’s outstanding publicly held interest to Novartis AG, a global pharmaceutical company

13-May-11
$NA
Australia flag
Target: 

Bionomics Ltd

Advised Bionomics Ltd, in relation to the tender process run by Bionomics’ largest shareholder, Start-up Australia Ventures (“Start-up”), for its 28% stake in the company, follow on sell-down of Start-up’s stake to 8% and associated capital raising by Bionomics

26-May-11
$192 million
Australia flag
Target: 

Centrebet International Limited

United Kingdom flag
Acquiror: 
Sportingbet plc

Advised Centrebet International, a leading International online wagering and gaming operator on the recommended cash offer by Sportingbet plc

21-Nov-11
$689 million
Australia flag
Target: 

iNova Pharmaceuticals

United States flag
Acquiror: 
Valeant Pharmaceuticals

Advised Archer Capital and Ironbridge Capital on the sale of iNova Pharmaceuticals, a leading pharmaceuticals company that sells and distributes a range of prescription and over-the-counter products in Australia, New Zealand, Asia and Southern Africa, to Valeant Pharmaceuticals

09-Jul-12
$4.7 billion
Netherlands flag
Target: 

ASML Holding NV (minority stake)

U.S.A., Taiwan, South Korea flags
Acquiror: 
Customers including Intel Corporation, TSMC and Samsung Electronics

Advised the Supervisory Board of ASML on the establishment of a Customer Co-Investment Program including the issue of 23% equity stake and $1.7 billion of R&D funding

01-Aug-12
$4.0 billion
South Africa, Switzerland flags
Target: 

Mediclinic International Limited

Advised Mediclinic International, South Africa’s second largest and Switzerland’s largest provider of private hospital services, on the restructuring of its entire balance sheet, including $2.2 billion debt refinancing in Switzerland and a $0.6 billion rights issue in South Africa

17-Oct-12
$2.6 billion
United States flag
Target: 

Cymer, Inc.

Netherlands flag
Acquiror: 
ASML Holding NV

Advised ASML Holding NV, a leading provider of lithography systems for the semiconductor industry, on its acquisition of Cymer, Inc., a leading supplier of lithography light sources used by chipmakers to manufacture advanced semiconductor devices

20-May-13
$8.5 billion
Ireland flag
Target: 

Warner Chilcott, plc

United States flag
Acquiror: 
Actavis, Inc.

Advised Actavis, Inc., a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, branded and biosimilar products on its acquisition of Warner Chilcott plc

31-May-13
$500 million
Australia flag
Target: 

iSelect (30% shareholding)

Australia flag
Acquiror: 
Ninemsn (T/A Mi9)

Advised Mi9, a joint venture between Microsoft and Nine Entertainment Co, and one of Australia’s leading digital media companies, on the sale of its 30% holding in iSelect, a leading Australian online-driven comparison service, as part of the Initial Public Offering of iSelect

18-Feb-14
$25.1 billion
United States flag
Target: 

Forest Laboratories Inc.

Ireland flag
Acquiror: 
Actavis plc

Advised Actavis plc, a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products on its acquisition of Forest Laboratories Inc.

27-Jun-14
$11 billion+
United Kingdom flag
Target: 

TUI Travel Plc

Germany flag
Acquiror: 
TUI AG

Advised TUI AG on the merger with TUI Travel Plc creating the world’s number one integrated leisure tourism business (+Transaction value represents enterprise value of combined entity)

28-Jul-14
$90 million
Australia flag
Target: 

Clinuvel Pharmaceuticals Limited

United States flag
Acquiror: 
Retrophin, Inc.

Advised Clinuvel, a biopharmaceutical company focused on developing drugs for the treatment of a range of severe skin disorders, in response to an unsolicited proposal to acquire the business from Retrophin, a pharmaceutical company focused on the development, acquisition and commercialization of drugs for the treatment of serious, catastrophic or rare diseases

Pages

show all